Distribution of blood eosinophils in patients with chronicobstructive pulmonary disease (COPD) living in areas ofendemic helminth infections: a cross-sectional study in South-East Asia (Helminth study)

Not Applicable

• Conditions: Health Condition 1: J708- Respiratory conditions due to other specified external agents

• Registration Number: CTRI/2019/01/017171
• Lead Sponsor: Glaxo Smith Kline

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Male or female at least 40 years old

2.Capable of giving written informed consent

3.Have a prior diagnosis of COPD documented in the medical record

4. Have COPD diagnosis confirmed by post-bronchodilator spirometry test at

enrolment

5. Have moderate-severe airflow limitation defined as a forced expiratory volume in

one second (FEV1)/forced vital capacity (FVC) less than 0.7 and FEV1 less than

80% predicted on post-bronchodilator spirometry at enrolment

Exclusion Criteria

1. Onset of COPD symptoms before 30 years of age

2. Experienced an acute exacerbation of COPD (defined as an acute worsening of

symptoms that result in treatment with an antibiotic or oral steroid) within the

four weeks prior to, or on the date of, enrolment

3. Have diagnosed asthma over the past 12 months or have experienced asthma

symptoms with a clinical history suggestive of asthma in the past 12 months

4. Have cystic fibrosis, pulmonary fibrosis or bronchiectasis documented in the

medical record

5. Have active tuberculosis or are taking medication for tuberculosis

6. Have had pulmonary resection surgery

7. Are pregnant (women of childbearing potential with positive urine pregnancy test

will be excluded)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome will include circulating blood eosinophil count; for each patient two <br/ ><br>estimates will be derived: cells per μL, and as % total white blood cell count (WCC).Timepoint: 1 year

Secondary Outcome Measures

Name	Time	Method
Primary outcome will include circulating blood eosinophil count; for each patient two <br/ ><br>estimates will be derived: cells per μL, and as % total white blood cell count (WCC).Timepoint: 1 Year